Free Trial
NASDAQ:GHRS

GH Research Q1 2024 Earnings Report

GH Research logo
$10.10 -1.08 (-9.66%)
Closing price 04:00 PM Eastern
Extended Trading
$10.13 +0.03 (+0.30%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GH Research EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

GH Research Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GH Research Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Friday, May 3, 2024
Conference Call Time
7:00AM ET

Earnings Documents

GH Research Earnings Headlines

GH Research (GHRS) to Release Earnings on Friday
Vanishing Benefits
What would you do if your next Social Security check simply never arrived? If you called and the line was dead… And the office was permanently closed? That's not some paranoid fantasy. It's the nightmare already unfolding across America—fueled by sweeping government cuts and a crumbling Social Security system.
GH Research initiated with a Buy at Guggenheim
Guggenheim starts GH Research at Buy, sees long-term upside potential
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS), together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

View GH Research Profile

More Earnings Resources from MarketBeat